{"id":49684,"date":"2022-10-17T14:02:17","date_gmt":"2022-10-17T12:02:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/"},"modified":"2022-10-17T14:02:17","modified_gmt":"2022-10-17T12:02:17","slug":"avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/","title":{"rendered":"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer"},"content":{"rendered":"
\n

\n– Replaces Founder Dr. A. Bruce Montgomery –<\/i>\n<\/p>\n

SEATTLE–(BUSINESS WIRE)–Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, announced the appointment of Lyn Baranowski as chief executive officer. Ms. Baranowski brings more than two decades of experience leading a vast array of functions in biotech, big pharma and venture capital firms.\n<\/p>\n

<\/a><\/p>\n

\n\u201cMy colleagues and I would like to express our gratitude to Dr. Montgomery, who brought Avalyn\u2019s lead programs successfully into clinical studies. Under his leadership, Avalyn built a strong scientific foundation, from which it will be well positioned to advance its business and clinical development objectives,\u201d stated Niall O’Donnell, chairman of the Avalyn board of directors. \u201cWe look forward to working with Ms. Baranowski, whose operational and strategic experience will be of vital importance as we enter this next phase of our evolution.\u201d\n<\/p>\n

\nMs. Baranowski added, \u201cThroughout my career, I have been driven by a passion to bring new respiratory medicines to patients with serious lung diseases who desperately need them. Avalyn\u2019s portfolio of inhaled products impressed me with its potential to target important pulmonary medicines directly to the site of disease, sparing unnecessary systemic tissue exposure. I am looking forward to working with and building the Avalyn team to advance the company\u2019s exciting clinical stage assets and build out our pipeline.\u201d\n<\/p>\n

\nPrior to joining Avalyn, Ms. Baranowski served as chief operating officer at Altavant Sciences, a biopharmaceutical company developing a portfolio of therapies for rare respiratory diseases. Earlier in her career, she served in senior-level corporate development and commercial roles, including vice president of commercial development at Pearl Therapeutics, which successfully developed a portfolio of COPD drugs prior to its sale to AstraZeneca for $1.15 Billion in 2013; and vice president in a healthcare-focused venture capital firm based in New York. She had previously held roles in business development, marketing and public affairs with Novartis Pharmaceuticals in Switzerland and the U.S.\n<\/p>\n

\nShe earned an MBA from Harvard Business School and a Bachelor of Arts from American University. In addition to her role at Avalyn, Ms. Baranowski serves on the board of directors of Rani Therapeutics, a company developing technology for the oral delivery of biologic drugs, and on the planning committee for the American Thoracic Society\u2019s Respiratory Innovation Summit, an annual meeting that unites the innovators, investors, and clinicians who are leading the fight to create powerful new treatments for deadly and crippling diseases of the lungs and airways.\n<\/p>\n

\nAbout Avalyn Pharma
\n
<\/b>Avalyn is a biopharmaceutical company developing targeted therapeutics for the treatment of rare respiratory diseases including idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD). ILDs are characterized by scarring, decline in lung function, reduced exercise capacity and quality of life, and are associated with increased mortality. Currently approved therapeutic options slow ILD progression but are associated with significant toxicities, which restrict their use and dosing. Avalyn is developing a pipeline of inhaled therapeutics designed to reduce systemic exposure and deliver medication to the site of disease. AP01, Avalyn\u2019s lead candidate, is an inhaled formulation of pirfenidone optimized for delivery via inhalation. In a recent clinical study of two doses assessed in 91 individuals with IPF, AP01 demonstrated the potential to improve both efficacy and safety over existing therapy. More information can be found at www.avalynpharma.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/span>
Marc Schneebaum
\n
Chief Financial Officer, Avalyn Pharma, Inc
\n
mschneebaum@avalynpharma.com<\/a>\n<\/p>\n

\nMedia:<\/span>
Aline Sherwood
\n
Scienta Communications
\n
asherwood@scientapr.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Replaces Founder Dr. A. Bruce Montgomery – SEATTLE–(BUSINESS WIRE)–Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, announced the appointment of Lyn Baranowski as chief executive officer. Ms. Baranowski brings more than two decades of experience leading a vast array of functions in biotech, big pharma … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49684","6":"format-standard","7":"category-industry"},"yoast_head":"\nAvalyn Pharma Appoints Lyn Baranowski Chief Executive Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Replaces Founder Dr. A. Bruce Montgomery – SEATTLE–(BUSINESS WIRE)–Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, announced the appointment of Lyn Baranowski as chief executive officer. Ms. Baranowski brings more than two decades of experience leading a vast array of functions in biotech, big pharma ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-17T12:02:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221014005420\/en\/1602682\/21\/Avalyn-logo-2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer\",\"datePublished\":\"2022-10-17T12:02:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/\"},\"wordCount\":586,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005420\\\/en\\\/1602682\\\/21\\\/Avalyn-logo-2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/\",\"name\":\"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005420\\\/en\\\/1602682\\\/21\\\/Avalyn-logo-2.jpg\",\"datePublished\":\"2022-10-17T12:02:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005420\\\/en\\\/1602682\\\/21\\\/Avalyn-logo-2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005420\\\/en\\\/1602682\\\/21\\\/Avalyn-logo-2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer - Pharma Trend","og_description":"– Replaces Founder Dr. A. Bruce Montgomery – SEATTLE–(BUSINESS WIRE)–Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, announced the appointment of Lyn Baranowski as chief executive officer. Ms. Baranowski brings more than two decades of experience leading a vast array of functions in biotech, big pharma ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-17T12:02:17+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221014005420\/en\/1602682\/21\/Avalyn-logo-2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer","datePublished":"2022-10-17T12:02:17+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/"},"wordCount":586,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221014005420\/en\/1602682\/21\/Avalyn-logo-2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/","url":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/","name":"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221014005420\/en\/1602682\/21\/Avalyn-logo-2.jpg","datePublished":"2022-10-17T12:02:17+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221014005420\/en\/1602682\/21\/Avalyn-logo-2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221014005420\/en\/1602682\/21\/Avalyn-logo-2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/avalyn-pharma-appoints-lyn-baranowski-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49684"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49684\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}